Terms: = Thyroid cancer AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Treatment
3 results:
1. Contribution of microRNA-30d to the prevention of the thyroid cancer occurrence and progression: mechanism and implications.
Li Y; He Y; Chen Y; He Z; Yang F; Xing C
Apoptosis; 2023 Apr; 28(3-4):576-593. PubMed ID: 36695983
[TBL] [Abstract] [Full Text] [Related]
2. RBM47/SNHG5/foxo3 axis activates autophagy and inhibits cell proliferation in papillary thyroid carcinoma.
Qin Y; Sun W; Wang Z; Dong W; He L; Zhang T; Lv C; Zhang H
Cell Death Dis; 2022 Mar; 13(3):270. PubMed ID: 35338124
[TBL] [Abstract] [Full Text] [Related]
3. Symptomatic Relief is Related to Serum Free Triiodothyronine Concentrations during Follow-up in Levothyroxine-Treated Patients with Differentiated thyroid cancer.
Larisch R; Midgley JEM; Dietrich JW; Hoermann R
Exp Clin Endocrinol Diabetes; 2018 Sep; 126(9):546-552. PubMed ID: 29396968
[TBL] [Abstract] [Full Text] [Related]
